# Rand Capital Corp: Form 10-Q for the period ended Jun 30, 2018

- Company: [Rand Capital Corp](/companies/rand.md) (CIK 81955)
- Form: 10-Q
- Filed: 2018-08-07
- Accepted by EDGAR: Aug 7, 2018, 08:01 ET
- Period: 2018-06-30
- Accession: 0001193125-18-240420
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/81955/000119312518240420/d552094d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/81955/000119312518240420/

## Management's discussion and analysis

As filed, 25,680 characters.

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the consolidated financial statements and related notes included elsewhere in this report. Historical results and percentage relationships among any amounts in the consolidated financial statements are not necessarily indicative of trends in operating results for any future periods.

### FORWARD LOOKING STATEMENTS

Statements included in this Management’s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report that do not relate to present or historical conditions are “forward-looking statements” within the meaning of that term in Section 27A of the Securities Act of 1933, as amended, and in Section 21E of the Securities Exchange Act of 1934, as amended. Additional oral or written forward-looking statements may be made by us from time to time, and forward-looking statements may be included in documents that are filed with the Securities and Exchange Commission. Forward-looking statements involve risks and uncertainties that could cause our results or outcomes to differ materially from those expressed in the forward-looking statements. Forward-looking statements may include, without limitation, statements relating to our plans, strategies, objectives, expectations and intentions and are intended to be made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “believes,” “forecasts,” “intends,” “possible,” “expects,” “estimates,” “anticipates,” or “plans” and similar expressions are intended to identify forward-looking statements. Among the important factors on which such statements are based are assumptions concerning the state of the United States economy and the local markets in which our portfolio companies operate, the state of the securities markets in which the securities of our portfolio companies could be traded, liquidity within the United States financial markets, and inflation. Forward-looking statements are also subject to the risks and uncertainties described under the caption “Risk Factors” contained in Part II, Item 1A of this report and in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2017.

There may be other factors not identified that affect the accuracy of our forward-looking statements. Further, any forward-looking statement speaks only as of the date when it is made and, except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time that may cause our business not to develop as we expect, and we cannot predict all of them.

### Overview

We are an internally managed investment company that lends to and invests in small companies often concurrently with other investors. We have elected to be treated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). As a BDC, we are required to comply with certain regulatory requirements. We have historically made the majority of our investments through our wholly-owned subsidiary, Rand Capital SBIC, Inc. (“Rand SBIC”), which operates as a small business investment company (“SBIC”) and has been licensed by the U.S. Small Business Administration (“SBA”) since 2002. During 2017 we established a second SBIC subsidiary, Rand Capital SBIC II, L.P. (“Rand SBIC II”) and began making investments through this SBIC subsidiary. During the first quarter of 2018, together with the SBA, we determined that the optimal structure was to revert back to investing in small businesses through our original SBIC, Rand SBIC, and the assets of Rand SBIC II were transferred to Rand SBIC. Rand SBIC has applied for an additional $6 million in new SBA leverage commitments and is currently undergoing the review and approval process.

### Outlook

At the end of the second quarter of 2018, we had approximately $4.7 million in cash available for future investments and expenses. We believe the combination of cash on hand, proceeds from portfolio exits, anticipated additional SBA leverage, and prospective investment income provide sufficient capital for us to continue to add new investments to our portfolio while reinvesting in existing portfolio companies that demonstrate continued growth potential. The following short and long-term trends provide us confidence in our ability to grow Rand:

- We expect that well run businesses will require capital to grow and should be able to compete effectively given the strong macroeconomic environment and eager reception of new technologies and service concepts.
- We continue to manage risk by investing with other investors, when possible.
- We are actively involved with the governance and management of our portfolio companies, which enables us to support their operating and marketing efforts and facilitate their growth.
- We have sufficient cash to invest in new opportunities and to opportunistically repurchase shares. At quarter end, we had authorization to repurchase an additional 458,954 shares of our common stock. However, our prioritized use of cash continues to be growing our portfolio.
- When our portfolio expands, we are able to better leverage our infrastructure.

### Critical Accounting Policies

We prepare our consolidated financial statements in accordance with United States generally accepted accounting principles (GAAP), which require the use of estimates and assumptions that affect the reported amounts of assets and liabilities. A summary of our critical accounting policies can be found in our Annual Report on Form 10-K for the year ended December 31, 2017 under Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

### Financial Condition

| Overview: | June 30, 2018 | December 31, 2017 | Decrease |  | % Decrease |
| --- | ---: | ---: | --- | ---: | ---: |
| Total assets | $38,870,649 | $40,133,913 | ($ | 1,263,264) | (3.1%) |
| Total liabilities | 8,103,671 | 8,215,228 |  | (111,557) | (1.4%) |
| Net assets | $30,766,978 | $31,918,685 | ($ | 1,151,707) | (3.6%) |

Net asset value per share (NAV) was $4.87 at June 30, 2018 and $5.05 at December 31, 2017.

Our gross outstanding SBA debentures at June 30, 2018 were $8,000,000 and will mature from 2022 through 2025. Cash approximated 15% of net assets at June 30, 2018, as compared to 20% at December 31, 2017.

### Composition of Our Investment Portfolio

Our financial condition is dependent on the success of our portfolio holdings. We have invested substantially all of our assets in small to medium-sized companies. The following summarizes our investment portfolio at the dates indicated.

|  | June 30, 2018 | December 31, 2017 | Increase | % Increase |
| --- | ---: | ---: | ---: | ---: |
| Investments, at cost | $37,940,613 | $36,689,319 | $1,251,294 | 3.4% |
| Unrealized depreciation, net | (5,613,187) | (4,405,257) | 1,207,930 | 27.4% |
| Investments at fair value | $32,327,426 | $32,284,062 | $43,364 | 0.1% |

Our total investments at fair value, as estimated by management and approved by our Board of Directors, approximated 105% of net assets at June 30, 2018 versus 101% of net assets at December 31, 2017.

The change in investments during the six months ended June 30, 2018, at cost, is comprised of the following:

| New investments: | Cost Increase (Decrease) |
| --- | ---: |
| KnowledgeVision Systems, Inc. (Knowledgevision) | $775,000 |
| SciAps, Inc. (Sciaps) | 250,000 |
| Centivo Corporation (Centivo) | 200,000 |
| Total of new investments | 1,225,000 |
| **Other changes to investments:** |  |
| Genicon Inc. (Genicon) interest conversion and OID amortization | 80,348 |
| Microcision LLC (Microcision) interest conversion | 9,582 |
| GoNoodle, Inc. (GoNoodle) interest conversion | 5,153 |
| Centivo interest conversion | 1,342 |
| Total of other changes to investments | 96,425 |
| **Investments repaid, sold or liquidated:** |  |
| Knoa Software Inc. (Knoa) repayment | (48,466) |
| Empire Genomics, LLC (Empire Genomics) repayment | (21,665) |
| Total of investments repaid, sold or liquidated | (70,131) |
| **Net change in investments, at cost** | **$1,251,294** |

36

### Results of Operations

Our principal investment objective is to achieve long-term capital appreciation on our equity investments while maintaining a current cash flow from our debt instruments and pass-through equity instruments to fund expenses. Therefore, we invest in a variety of financial instruments to provide a current return on a portion of the investment portfolio.

### Comparison of the three months ended June 30, 2018 to the three months ended June 30, 2017

### Investment Income

|  | Three months ended June 30, 2018 | Three months ended June 30, 2017 | Increase | % Increase |
| --- | ---: | ---: | ---: | ---: |
| Interest from portfolio companies | $315,700 | $277,640 | $38,060 | 13.7% |
| Interest from other investments | 7,735 | 6,859 | 876 | 12.8% |
| Dividend and other investment income | 78,942 | 55,705 | 23,237 | 41.7% |
| Fee income | 11,141 | 8,935 | 2,206 | 24.7% |
| Total investment income | $413,518 | $349,139 | $64,379 | 18.4% |

Interest from portfolio companies – Interest from portfolio companies was approximately 14% higher during the three months ended June 30, 2018 versus the same period in 2017 due to the fact that we have originated more income-producing debt investments in the last year. The new debt instruments were originated from Genicon Inc. (Genicon), eHealth Global Technologies, Inc. (eHealth) and several other portfolio companies.

The following investments are on non-accrual status: G-TEC Natural Gas Systems (G-Tec), First Wave Products Group, LLC (First Wave), OnCore Golf Technology, Inc. (Oncore) and portions of the Empire Genomics, LLC (Empire Genomics) and Mercantile Adjustment Bureau, LLC (Mercantile) outstanding loan balances.

Interest from other investments - The increase in interest from other investments is primarily due to higher average cash balances during the three months ended June 30, 2018 versus the same period in 2017.

Dividend and other investment income - Dividend income is comprised of cash distributions from limited liability companies (LLCs) and corporations in which we have invested. Our investment agreements with certain LLCs require those LLCs to distribute funds to us for payment of income taxes on our allocable share of the LLC’s profits. These portfolio companies may also elect to make additional discretionary distributions. Dividend income will fluctuate based upon the profitability of these LLCs and corporations and the timing of the distributions or the impact of new investments or divestitures. The dividend distributions for the respective periods were:

|  | Three months ended June 30, 2018 | Three months ended June 30, 2017 |
| --- | ---: | ---: |
| Carolina Skiff LLC (Carolina Skiff) | $39,169 | $42,000 |
| New Monarch Machine Tool, Inc. (New Monarch) | 27,409 | — |
| Tilson Technology Management, Inc. (Tilson) | 9,687 | 5,000 |
| Empire Genomics LLC (Empire Genomics) | 2,677 | 2,681 |
| SOMS Technologies, LLC (SOMS) | — | 6,024 |
| Total dividend and other investment income | $78,942 | $55,705 |

Fee income - Fee income consists of the revenue associated with the amortization of financing fees charged to the portfolio companies upon successful closing of SBIC financings and income from portfolio company board attendance fees. The financing fees are amortized ratably over the life of the instrument associated with the fees. The unamortized fees are carried on the balance sheet under the line item “Deferred revenue.”

The income associated with the amortization of financing fees was $10,141 and $7,935 for the three months ended June 30, 2018 and 2017, respectively. The income from board fees was $1,000 for each of the three months ended June 30, 2018 and 2017, respectively.

### Expenses

|  | Three months ended June 30, 2018 | Three months ended June 30, 2017 | Decrease |  | % Decrease |
| --- | ---: | ---: | --- | ---: | ---: |
| Total expenses | $473,670 | $607,163 | ($ | 133,493) | (22.0%) |

Expenses predominately consist of interest expense on outstanding SBA borrowings, compensation expense, and general and administrative expenses, including stockholder and office operating expenses and professional fees.

The decrease in expenses during the three months ended June 30, 2018 versus the same period in 2017 was primarily caused by a 79%, or $140,852, decrease in professional fees. Professional fees were higher during 2017 versus 2018 because we incurred additional expenses in connection with developing and implementing our long-term growth strategy during 2017. These expenses included external legal, tax consulting and other advisory expenses to support refinement of our strategy, which involved assessing options relative to the complex regulatory environment in which we operate.

In addition, for the three months ended June 30, 2018 there was a $30,741 charge to bad debt expense while there was no bad debt expense for the three months ended June 30, 2017.

### Increase in Unrealized Depreciation of Investments

|  | Three months ended June 30, 2018 |  | Three months ended June 30, 2017 |  | Increase |
| --- | --- | ---: | --- | ---: | ---: |
| Increase in unrealized depreciation of investments before income taxes | ($ | 756,441) | ($ | 718,339) | $38,102 |

The increase in unrealized depreciation, before income taxes, for the three months ended June 30, 2018 was comprised of the following:

|  | Three months ended June 30, 2018 |  |
| --- | --- | ---: |
| Empire Genomics, LLC (Empire Genomics) | ($ | 450,000) |
| SOMS Technologies, LLC (SOMS) |  | (498,348) |
| GiveGab, Inc. (Givegab) |  | 191,907 |
| **Total increase in net unrealized depreciation of investments before income taxes during the three months ended June 30, 2018** | ($ | 756,441) |

The valuations of our investments in Empire Genomics and SOMS were decreased after we reviewed each of the portfolio company’s operations and current and projected financial condition and determined that a valuation adjustment was necessary.

Givegab’s value was increased to the cost basis of the investment after a financial analysis of the portfolio company indicating continued improved performance.

The increase in unrealized depreciation, before income taxes, for the three months ended June 30, 2017 was comprised of the following:

|  | Three months ended June 30, 2017 |  |
| --- | --- | ---: |
| City Dining Cards, Inc. (Loupe) | ($ | 250,000) |
| Teleservices Solutions Holdings, LLC (Teleservices) |  | (395,398) |
| SciAps, Inc. (Sciaps) |  | (300,000) |
| Athenex, Inc. (Athenex) |  | 197,336 |
| BeetNPath, LLC (Beetnpath) |  | 29,723 |
| **Total increase in net unrealized depreciation of investments before income taxes during the three months ended June 30, 2017** | ($ | 718,339) |

The valuations of our investments in Loupe and Teleservices were decreased after we reviewed each portfolio company and its current and projected financial condition and determined that a valuation adjustment was necessary.

The valuation of Sciaps was decreased to revalue our equity holdings based upon the liquidation preferences of our securities as compared to the most recent equity round of financing completed by Sciaps.

In accordance with our valuation policy, we increased the value of our investment in Beetnpath based on a significant equity financing by a new non-strategic outside entity.

Athenex completed an Initial Public Offering (IPO) during the second quarter of 2017 and its shares of common stock became publicly traded on the NASDAQ Global Select Market under the symbol “ATNX”. We held 46,296 shares of the common stock of Athenex and valued the shares using the three day average bid price for the last three trading days of the reporting period, which was then discounted due to restrictions on the sale of the shares.

All of these value adjustments resulted from a review by our management using the guidance set forth by ASC 820 and our established valuation policy.

### Net Increase (Decrease) in Net Assets from Operations

We account for our operations under GAAP for investment companies. The principal measure of our financial performance is “net increase (decrease) in net assets from operations” on our consolidated statements of operations. For the three months ended June 30, 2018 and 2017, the net decrease in net assets from operations was ($631,294) and ($635,337), respectively.

### Comparison of the six months ended June 30, 2018 to the six months ended June 30, 2017

### Investment Income

|  | Six months ended June 30, 2018 | Six months ended June 30, 2017 | Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Interest from portfolio companies | $613,048 | $523,731 | $89,317 | 17.1% |
| Interest from other investments | 12,845 | 17,834 | (4,989) | (28.0%) |
| Dividend and other investment income | 133,107 | 120,590 | 12,517 | 10.4% |
| Fee income | 17,327 | 15,621 | 1,706 | 10.9% |
| Total investment income | $776,327 | $677,776 | $98,551 | 14.5% |

39

Interest from portfolio companies – Interest from portfolio companies was approximately 17% higher during the six months ended June 30, 2018 versus the same period in 2017 due to the fact that we have originated more income-producing debt investments in the last year. These new debt instruments were originated from Genicon Inc. (Genicon) and eHealth Global Technologies, Inc. and several other portfolio companies.

The following investments are on non-accrual status: G-TEC Natural Gas Systems (G-Tec), First Wave Products Group, LLC (First Wave), OnCore Golf Technology, Inc. (Oncore) and a portion of the Empire Genomics, LLC (Empire Genomics) and Mercantile Adjustment Bureau, LLC (Mercantile) outstanding loan balance.

Interest from other investments - The decrease in interest from other investments is primarily due to lower average cash balances during the six months ended June 30, 2018 versus the same period in 2017.

Dividend and other investment income - The dividend distributions for the respective periods were:

|  | Six months ended June 30, 2018 | Six months ended June 30, 2017 |
| --- | ---: | ---: |
| Carolina Skiff LLC (Carolina Skiff) | $80,264 | $99,373 |
| New Monarch Machine Tool, Inc. (New Monarch) | 27,409 | — |
| Tilson Technology Management, Inc. (Tilson) | 19,376 | 10,000 |
| Empire Genomics LLC (Empire Genomics) | 6,058 | 5,193 |
| SOMS Technologies, LLC (SOMS) | — | 6,024 |
| Total dividend and other investment income | $133,107 | $120,590 |

Fee income - The income associated with the amortization of financing fees was $15,327 and $14,621 for the six months ended June 30, 2018 and 2017, respectively. The income from board fees was $2,000 and $1,000 for the six months ended June 30, 2018 and 2017, respectively.

### Expenses

|  | Six months ended June 30, 2018 | Six months ended June 30, 2017 | Decrease |  | % Decrease |
| --- | ---: | ---: | --- | ---: | ---: |
| Total expenses | $1,062,234 | $1,123,572 | ($ | 61,338) | (5.5%) |

The decrease in expenses during the six months ended June 30, 2018 versus the same period in 2017 was primarily caused by a 47%, or $123,167, decrease in professional fees. Professional fees were higher during 2017 versus 2018 because we incurred additional expenses in connection with developing and implementing our long-term growth strategy during 2017. This decrease was offset by a $76,641 charge to bad debt expense for the six months ended June 30, 2018 while there was no bad debt expense for the six months ended June 30, 2018.

### Increase in Unrealized Depreciation of Investments

|  | Six months ended June 30, 2018 |  | Six months ended June 30, 2017 |  | Increase |
| --- | --- | ---: | --- | ---: | ---: |
| Increase in unrealized depreciation of investments before income taxes | ($ | 1,207,930) | ($ | 1,098,983) | $108,947 |

40

The increase in unrealized depreciation, before income taxes, for the six months ended June 30, 2018 was comprised of the following:

|  | Six months ended June 30, 2018 |  |
| --- | --- | ---: |
| Empire Genomics, LLC (Empire Genomics) | ($ | 651,489) |
| SOMS Technologies, LLC (SOMS) |  | (498,348) |
| First Wave Products Group (First Wave) |  | (250,000) |
| GiveGab, Inc. (Givegab) |  | 191,907 |
| **Total increase in net unrealized depreciation of investments before income taxes during the six months ended June 30, 2018** | ($ | 1,207,930) |

The valuations of our investments in Empire Genomics and SOMS were decreased after we reviewed each of the portfolio company’s operations and current and projected financial condition and determined that a valuation adjustment was necessary.

Our valuation of First Wave was decreased to reflect an anticipated round of financing expected to be completed by First Wave in the third quarter of 2018.

Givegab’s value was increased to the cost basis of the investment after a financial analysis of the portfolio company indicating continued improved performance.

The increase in unrealized depreciation, before income taxes, for the six months ended June 30, 2017 was comprised of the following:

|  | Six months ended June 30, 2017 |  |
| --- | --- | ---: |
| City Dining Cards, Inc. (Loupe) | ($ | 500,000) |
| Teleservices Solutions Holdings, LLC (Teleservices) |  | (395,398) |
| SciAps, Inc. (Sciaps) |  | (300,000) |
| Mercantile Adjustment Bureau, LLC (Mercantile) |  | (250,000) |
| Athenex, Inc. (Athenex) |  | 197,336 |
| ACV Auctions, Inc. (ACV) |  | 119,356 |
| BeetNPath, LLC (Beetnpath) |  | 29,723 |
| **Total increase in net unrealized depreciation of investments before income taxes during the six months ended June 30, 2017** | ($ | 1,098,983) |

The valuations of our investments in Loupe, Mercantile and Teleservices were decreased after we reviewed each portfolio company and its current and projected financial condition and determined that a valuation adjustment was necessary.

The valuation of Sciaps was decreased to revalue our equity holdings based upon the liquidation preferences of our securities as compared to the most recent equity round of financing completed by Sciaps.

In accordance with our valuation policy, we increased the value of our investments in ACV and Beetnpath based on a significant equity financing by a new non-strategic outside entity.

Athenex completed an Initial Public Offering (IPO) during the second quarter of 2017 and its shares of common stock were traded on the NASDAQ Global Select Market under the symbol “ATNX”. As of June 30, 2017 we held 46,296 shares of the common stock of Athenex and valued these shares using the three day average bid price for the last three trading days of the reporting period, which was then discounted due to restrictions on the sale of the shares.

All of these value adjustments resulted from a review by our management using the guidance set forth by ASC 820 and our established valuation policy.

### Net Decrease in Net Assets from Operations

We account for our operations under GAAP for investment companies. The principal measure of our financial performance is “net decrease in net assets from operations” on our consolidated statements of operations. For the six months ended June 30, 2018 and 2017, the net decrease in net assets from operations was ($1,151,707) and ($994,818), respectively.

### Liquidity and Capital Resources

Our principal long-term objective is to achieve growth in net asset value per share through capital appreciation. Therefore, a significant portion of our investment portfolio is structured to maximize the potential for capital appreciation, and certain portfolio investments may be structured to provide little or no current yield in the form of dividends or interest payments.

As of June 30, 2018, our total liquidity consisted of approximately $4.7 million in cash on hand.

Net cash provided by operating activities has averaged approximately $433,000 over the last three years. The average cash used for investment in portfolio companies over the last three years was approximately $3,000,000. Our cash flow from operations may fluctuate based on the timing of the receipt of dividend income and realized gains and the associated income taxes paid. We will generally use cash to fund our operating expenses and also to invest in companies, as we seek to build our portfolio utilizing our available cash and proceeds from liquidations of portfolio investments. We anticipate that we will continue to exit investments. However, the timing of liquidation events within the portfolio is difficult to project with any certainty. As of June 30, 2018, we did not have any outstanding commitments to borrow funds from the SBA. Starting in 2022, our SBA debt begins to reach maturity, and this will require us to identify sources of future funding if liquidation of investments is not sufficient to fund operations and repay the SBA debt obligation.

We believe that the cash on hand at June 30, 2018, the scheduled interest payments on our portfolio investments and the anticipated additional SBA leverage will be sufficient to meet our cash needs for the next twelve months. We continue to seek potential exits from portfolio companies to increase the amount of liquidity available for new investments, operating activities and future SBA debenture repayment obligations.

## Market risk

As filed, 1,783 characters.

Our investment activities contain elements of risk. Our investment portfolio consists of equity and debt securities in private companies and is subject to valuation risk. Because there is typically no public market for the equity and debt securities in which we invest, the valuation of the equity interests in the portfolio is stated at “fair value” as determined in good faith by our management and approved by our Board of Directors. This is in accordance with our investment valuation policy (see the discussion of valuation policy contained in “Note 3. Investments” in the consolidated financial statements contained in Item 1 of this report, which is hereby incorporated herein by reference.) In the absence of readily ascertainable market values, the estimated value of the portfolio may differ significantly from the values that would be placed on the portfolio if a ready market for the investments existed. Any changes in valuation are recorded on the consolidated statement of operations as “Net change in unrealized depreciation on investments.”

At times, a portion of our portfolio may include marketable securities traded in the over-the-counter market. In addition, there may be a portion of the portfolio for which no regular trading market exists. In order to realize the full value of a security, the market must trade in an orderly fashion or a willing purchaser must be available when a sale is to be made. Should an economic or other event occur that would not allow markets to trade in an orderly fashion, we may not be able to realize the fair value of our marketable investments or other investments in a timely manner.

As of June 30, 2018 we did not have any off-balance sheet arrangements or hedging or similar derivative financial instrument investments.

## Controls and procedures

As filed, 1,360 characters.

*Disclosure Controls and Procedures.* The Corporation maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that this information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. The Chief Executive Officer and the Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of the Corporation’s disclosure controls and procedures as June 30, 2018. Based on the evaluation of these disclosure controls and procedures, the Chief Executive Officer and Chief Financial Officer concluded that the Corporation’s controls and procedures were effective as of June 30, 2018.

*Changes in Internal Control over Financial Reporting.* There have been no changes in our internal control over financial reporting during the Corporation’s most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Corporation’s internal control over financial reporting.

### PART II.

### OTHER INFORMATION

Filed Aug 7, 2018.
Source: SEC EDGAR, the filing index for accession 0001193125-18-240420. Last ingested by Listed: Nov 4, 2026, 08:48 ET. No prices; not investment advice.
